Boundless Bio, INC. (BOLD) — 10-Q Filings

10-Q Filings (6)

• Boundless Bio Narrows Q3 Loss Amidst R&D Cuts, Cash Dwindles — Nov 5, 2025 Risk: high
  Boundless Bio, Inc. reported a net loss of $13.879 million for the three months ended September 30, 2025, an improvement from the $16.509 million net loss in th
• Boundless Bio's Q2 Net Loss Widens to $29.8M Amid R&D Surge — Aug 5, 2025 Risk: high
  Boundless Bio, Inc. (BOLD) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage as a pharmaceutical pr
• Boundless Bio Files Q1 2025 10-Q — May 9, 2025 Risk: medium
  Boundless Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial position and results of operations. Key financial da
• Boundless Bio Q3 2024 10-Q Filed — Nov 7, 2024 Risk: medium
  Boundless Bio, Inc. filed its 10-Q for the period ending September 30, 2024. The company's financial statements show various equity and debt instruments, includ
• Boundless Bio Files 10-Q, Details Financials — Aug 12, 2024 Risk: medium
  Boundless Bio, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial status, including details on its convertible preferre
• Boundless Bio, Inc. Files 10-Q for Period Ending March 31, 2024 — May 13, 2024 Risk: medium
  Boundless Bio, Inc. (BOLD) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Boundless Bio, Inc. filed a 10-Q for the quarterly period ended March 3

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX